Tumor volume is a better prognostic factor than greatest tumor diameter in stage ia non-small cell lung cancer

C. H. Tsai, C. M. Lin, C. C. Hsieh, W. H. Hsu, H. W. Wang, Liang Shun Wang

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: The objective was to determine whether tumor volume, calculated by multiplying 3-dimensional diameters recorded from surgical specimens, could represent tumor size more precisely than the currently used greatest tumor diameter (T status) as a prognostic factor in early-stage non-small cell lung cancer (NSCLC). Methods: From 1991 to 2001, a total of 236 stage Ia NSCLC patients underwent curative resection in our institution. Their clinicopathological factors were retrospectively reviewed. The cases were grouped according to stereographic tumor size. Group 1 included tumor volumes less than 0.5236 (13 × π/6) cm3, Group 2 included tumor volumes between 0.5236 - 4.1888 (23 × π/ 6) cm 3, while Group 3 included tumor volumes between 4.188-14.1372 (3 3 × π/6) cm3. Overall survival and disease-free interval analyses were performed with the Kaplan-Meier method and multivariable Cox's proportional hazard model. Tumor volume and other clinico-pathological factors were included for analysis. Results: Median follow-up was 55.5 months. The overall 5- and 10-year survival rates were 78% and 71%, and the 5- and 10-year disease-free intervals were 68% and 64%, respectively. The overall survival (p = 0.0075) and disease-free interval (p = 0.0025) showed significant differences between tumor volume groups. Smoking history, presence of symptoms and the number of resected lymph nodes were also significantly related to overall survival and disease-free interval. Conclusion: The products of 3-D diameters (tumor volume) more precisely evaluated tumor size as well as survival of patients with stage la NSCLC.

Original languageEnglish
Pages (from-to)537-543
Number of pages7
JournalThoracic and Cardiovascular Surgeon
Volume54
Issue number8
DOIs
Publication statusPublished - Dec 2006
Externally publishedYes

Fingerprint

Tumor Burden
Non-Small Cell Lung Carcinoma
Neoplasms
Disease-Free Survival
Survival
Proportional Hazards Models
Survival Rate
Lymph Nodes
Smoking
History

Keywords

  • Non-small cell lung cancer
  • Thoracic surgery
  • Tumor size
  • Tumor volume

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Tumor volume is a better prognostic factor than greatest tumor diameter in stage ia non-small cell lung cancer. / Tsai, C. H.; Lin, C. M.; Hsieh, C. C.; Hsu, W. H.; Wang, H. W.; Wang, Liang Shun.

In: Thoracic and Cardiovascular Surgeon, Vol. 54, No. 8, 12.2006, p. 537-543.

Research output: Contribution to journalArticle

Tsai, C. H. ; Lin, C. M. ; Hsieh, C. C. ; Hsu, W. H. ; Wang, H. W. ; Wang, Liang Shun. / Tumor volume is a better prognostic factor than greatest tumor diameter in stage ia non-small cell lung cancer. In: Thoracic and Cardiovascular Surgeon. 2006 ; Vol. 54, No. 8. pp. 537-543.
@article{459a04e622914887ad551fe767d69055,
title = "Tumor volume is a better prognostic factor than greatest tumor diameter in stage ia non-small cell lung cancer",
abstract = "Objective: The objective was to determine whether tumor volume, calculated by multiplying 3-dimensional diameters recorded from surgical specimens, could represent tumor size more precisely than the currently used greatest tumor diameter (T status) as a prognostic factor in early-stage non-small cell lung cancer (NSCLC). Methods: From 1991 to 2001, a total of 236 stage Ia NSCLC patients underwent curative resection in our institution. Their clinicopathological factors were retrospectively reviewed. The cases were grouped according to stereographic tumor size. Group 1 included tumor volumes less than 0.5236 (13 × π/6) cm3, Group 2 included tumor volumes between 0.5236 - 4.1888 (23 × π/ 6) cm 3, while Group 3 included tumor volumes between 4.188-14.1372 (3 3 × π/6) cm3. Overall survival and disease-free interval analyses were performed with the Kaplan-Meier method and multivariable Cox's proportional hazard model. Tumor volume and other clinico-pathological factors were included for analysis. Results: Median follow-up was 55.5 months. The overall 5- and 10-year survival rates were 78{\%} and 71{\%}, and the 5- and 10-year disease-free intervals were 68{\%} and 64{\%}, respectively. The overall survival (p = 0.0075) and disease-free interval (p = 0.0025) showed significant differences between tumor volume groups. Smoking history, presence of symptoms and the number of resected lymph nodes were also significantly related to overall survival and disease-free interval. Conclusion: The products of 3-D diameters (tumor volume) more precisely evaluated tumor size as well as survival of patients with stage la NSCLC.",
keywords = "Non-small cell lung cancer, Thoracic surgery, Tumor size, Tumor volume",
author = "Tsai, {C. H.} and Lin, {C. M.} and Hsieh, {C. C.} and Hsu, {W. H.} and Wang, {H. W.} and Wang, {Liang Shun}",
year = "2006",
month = "12",
doi = "10.1055/s-2006-924479",
language = "English",
volume = "54",
pages = "537--543",
journal = "Thoracic and Cardiovascular Surgeon",
issn = "0171-6425",
publisher = "Georg Thieme Verlag",
number = "8",

}

TY - JOUR

T1 - Tumor volume is a better prognostic factor than greatest tumor diameter in stage ia non-small cell lung cancer

AU - Tsai, C. H.

AU - Lin, C. M.

AU - Hsieh, C. C.

AU - Hsu, W. H.

AU - Wang, H. W.

AU - Wang, Liang Shun

PY - 2006/12

Y1 - 2006/12

N2 - Objective: The objective was to determine whether tumor volume, calculated by multiplying 3-dimensional diameters recorded from surgical specimens, could represent tumor size more precisely than the currently used greatest tumor diameter (T status) as a prognostic factor in early-stage non-small cell lung cancer (NSCLC). Methods: From 1991 to 2001, a total of 236 stage Ia NSCLC patients underwent curative resection in our institution. Their clinicopathological factors were retrospectively reviewed. The cases were grouped according to stereographic tumor size. Group 1 included tumor volumes less than 0.5236 (13 × π/6) cm3, Group 2 included tumor volumes between 0.5236 - 4.1888 (23 × π/ 6) cm 3, while Group 3 included tumor volumes between 4.188-14.1372 (3 3 × π/6) cm3. Overall survival and disease-free interval analyses were performed with the Kaplan-Meier method and multivariable Cox's proportional hazard model. Tumor volume and other clinico-pathological factors were included for analysis. Results: Median follow-up was 55.5 months. The overall 5- and 10-year survival rates were 78% and 71%, and the 5- and 10-year disease-free intervals were 68% and 64%, respectively. The overall survival (p = 0.0075) and disease-free interval (p = 0.0025) showed significant differences between tumor volume groups. Smoking history, presence of symptoms and the number of resected lymph nodes were also significantly related to overall survival and disease-free interval. Conclusion: The products of 3-D diameters (tumor volume) more precisely evaluated tumor size as well as survival of patients with stage la NSCLC.

AB - Objective: The objective was to determine whether tumor volume, calculated by multiplying 3-dimensional diameters recorded from surgical specimens, could represent tumor size more precisely than the currently used greatest tumor diameter (T status) as a prognostic factor in early-stage non-small cell lung cancer (NSCLC). Methods: From 1991 to 2001, a total of 236 stage Ia NSCLC patients underwent curative resection in our institution. Their clinicopathological factors were retrospectively reviewed. The cases were grouped according to stereographic tumor size. Group 1 included tumor volumes less than 0.5236 (13 × π/6) cm3, Group 2 included tumor volumes between 0.5236 - 4.1888 (23 × π/ 6) cm 3, while Group 3 included tumor volumes between 4.188-14.1372 (3 3 × π/6) cm3. Overall survival and disease-free interval analyses were performed with the Kaplan-Meier method and multivariable Cox's proportional hazard model. Tumor volume and other clinico-pathological factors were included for analysis. Results: Median follow-up was 55.5 months. The overall 5- and 10-year survival rates were 78% and 71%, and the 5- and 10-year disease-free intervals were 68% and 64%, respectively. The overall survival (p = 0.0075) and disease-free interval (p = 0.0025) showed significant differences between tumor volume groups. Smoking history, presence of symptoms and the number of resected lymph nodes were also significantly related to overall survival and disease-free interval. Conclusion: The products of 3-D diameters (tumor volume) more precisely evaluated tumor size as well as survival of patients with stage la NSCLC.

KW - Non-small cell lung cancer

KW - Thoracic surgery

KW - Tumor size

KW - Tumor volume

UR - http://www.scopus.com/inward/record.url?scp=34247169980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247169980&partnerID=8YFLogxK

U2 - 10.1055/s-2006-924479

DO - 10.1055/s-2006-924479

M3 - Article

VL - 54

SP - 537

EP - 543

JO - Thoracic and Cardiovascular Surgeon

JF - Thoracic and Cardiovascular Surgeon

SN - 0171-6425

IS - 8

ER -